Please sign in to follow a disease.
Which CoQ10 supplement works best? new study aims to find out
NCT ID NCT07255079
First seen Jun 27, 2026 · Last updated Jul 09, 2026 · Updated 2 times
Summary
This trial will test three different forms of Coenzyme Q10 (CoQ10) supplements in 20 healthy adults to see which one is absorbed best by the body. Participants will take each supplement at different times, and blood levels will be measured over 72 hours. The goal is to identify the most effective formulation for boosting CoQ10 levels.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- Coenzyme Q10 (CoQ10) dietary supplements in capsule and liquid forms
- What this could lead to
- If successful, this study could show which CoQ10 formulation is best absorbed, helping people choose a more effective supplement.
- What could go wrong
- This is a small, early-stage trial in healthy volunteers, not patients. Results may not apply to people with health conditions, and the study only measures absorption, not health benefits.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
20 people
The number who actually took part.
- Started
-
Apr 2026
- Finished
-
Jun 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 to 60 years
- Sex
-
Female participants only
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: 1. Males and females 18 to 60 years of age, inclusive 2. BMI between 18.5 to 29.9 Kg/m3, inclusive 3. Females not of child-bearing potential, defined as those who have undergone a sterilization procedure (e.g. hysterectomy, bilateral oophorectomy, bilateral tubal ligation, complete endometrial ablation) or have been post-menopausal for at least 1 year prior to screening Or, Individuals of child-bearing potential must have a negative baseline urine pregnancy test and agree to use a medically approved method of birth control for the duration of the study. All hormonal birth control must have been in use for a minimum of three months. Acceptable methods of birth control include: * Hormonal contraceptives including oral contraceptives, hormone birth control patch (Ortho Evra), vaginal contraceptive ring (NuvaRing), injectable contraceptives (Depo-Provera, Lunelle), or hormone implant (Norplant System) * Double-barrier method * Intrauterine devices * Non-heterosexual lifestyle and agrees to use contraception if planning on changing to heterosexual partner(s) * Vasectomy of partner at least 6 months prior to screening * Abstinence and agrees to use contraception if planning on becoming sexually active during the study 4. Willingness to complete questionnaires and diaries associated with the study and complete all study requirements 5. Agrees to maintain current lifestyle (diet, physical activity, medications, supplements, and sleep) as much as possible within study specific requirements throughout the study 6. Provided voluntary, written, informed consent to participate in the study 7. Healthy as determined by medical history and laboratory results as assessed by the Qualified Investigator (QI) Exclusion Criteria: 1. Individuals who are pregnant, breast feeding, or planning to become pregnant during the study 2. Poor venous access, as assessed by the QI 3. Allergy, sensitivity, intolerance, or dietary restriction preventing consumption of investigational products or comparator ingredients or inability to consume the standardized meals 4. Following a specific diet (e.g. vegetarian, carnivore, paleo, vegan, etc.…) 5. Unstable metabolic disease or chronic diseases as assessed by the QI 6. Current or history of any significant diseases of the gastrointestinal tract as assessed by the QI 7. Unstable hypertension. Treatment on a stable dose of medication for at least 3 months will be considered by the QI 8. Type I or Type II diabetes 9. Significant cardiovascular event in the past 6 months. Participants with no significant cardiovascular event on stable medication may be included after assessment by the QI on a case-by-case basis 10. History of or current diagnosis with kidney and/or liver diseases as assessed by the QI on a case-by-case basis, with the exception of history of kidney stones in participants who are symptom free for 6 months 11. Self-reported confirmation of current or pre-existing thyroid condition. Treatment on a stable dose of medication for at least 3 months will be considered by the QI 12. Major surgery in the past 3 months or individuals who have planned surgery during the course of the study. Participants with minor surgery will be considered on a case-by-case basis by the QI 13. Cancer, except skin basal cell carcinoma completely excised with no chemotherapy or radiation with a follow up that is negative. Volunteers with cancer in full remission for more than five years after diagnosis are acceptable 14. Individuals with an autoimmune disease or are immune compromised as assessed by the QI 15. Self-reported confirmation of a HIV-, Hepatitis B- and/or C-positive diagnosis as assessed by the QI 16. Self-reported confirmation of blood/bleeding disorders as assessed by the QI 17. Use of prescribed cannabinoid products 18. Chronic use of cannabinoid products (\>2 times/week). Occasional users will be required to washout and abstain for the duration of the study period 19. Regular use of tobacco or nicotine products in the past six months, as assessed by the QI. Occasional users will be required to washout and abstain for the duration of the study period 20. Alcohol intake average of \>2 standard drinks per day as assessed by the QI 21. Alcohol or drug abuse within the last 12 months 22. Current use of prescribed and/or over-the-counter (OTC) medications, supplements, and/or consumption of food/drinks that may impact the efficacy and/or safety of the investigational product (Sections 7.3.1 and 7.3.2) 23. Clinically significant abnormal laboratory results at screening as assessed by the QI 24. Significant blood loss or blood donation totaling between 101 mL to 449 mL of blood within 30 days prior to Visit 2 or a blood donation of more than 450 mL within 56 days prior to Visit 2 25. Participation in other clinical research studies 30 days prior to baseline, as assessed by the QI 26. Individuals who are unable to give informed consent 27. Any other condition or lifestyle factor, that, in the opinion of the QI, may adversely affect the participant's ability to complete the study or its measures or pose significant risk to the participant
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Bioavailability heathy volunteers are added.
Genom att skicka in godkänner du våra Användarvillkor
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
KGK Science Inc.
London, Ontario, N6B3L1, Canada
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Seaweed crackers: a superfood delivery system?
- New combo pill for fluid retention passes first Body-Processing test in healthy volunteers
- New glutathione formula shows promise in small study
- Breastfeeding and meds: new study aims to uncover hidden risks for babies
- Does food change how this heart pill works? new study investigates
- New trazodone formula tested for similarity to current version